Axsome医疗 AXSM 深 沪
等待开盘 08-20 09:30:00 美东时间
111.29
+0.160
+0.14%
华盛通- 最 高112.09
- 今 开111.00
- 成交量 61.82万股
- 最 低 109.60
- 昨 收 111.13
- 总市值 54.80亿
- 52周最高 139.1299
- 市盈率 静 --
- 换手率 1.26%
- 52周最低 75.56
- 委 比 28.04%
- 总股本 4923.64万
- 历史最高 139.1299
- 量 比 1.22
- 振 幅 2.24%
- 历史最低 1.94
- 每 手 1
- 风险率 9.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years
FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.
08-18 21:45
Axsome Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
Axsome Therapeutics shares are trading higher after the company reported better...
08-04 20:33
Needham Reiterates Buy on Axsome Therapeutics, Maintains $150 Price Target
Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $150 price target.
08-04 20:02
Axsome Therapeutics Reports Strong Q2 2025 Performance
An update from Axsome Therapeutics ( ($AXSM) ) is now available. On August 4, 2...
08-04 19:58
Axsome Therapeutics Q2 Adj. EPS $(0.47) Beats $(1.07) Estimate, Sales $150.04M Beat $140.33M Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(1.07) by 56.2 percent. This is a 58.04 percent increase over losses of $(1.12) per share
08-04 19:02
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
A Look at Axsome Therapeutics's Upcoming Earnings Report
Axsome Therapeutics (NASDAQ:AXSM) is preparing to release its quarterly earning...
08-02 01:04
Axsome Therapeutics Spotlights Broad Clinical Pipeline In Alzheimer's Agitation, MDD, Narcolepsy, And Fibromyalgia At New York Investor Event
Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analysesPresentations by expert clinicians and key opinion
07-21 19:37
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
Axsome Therapeutics will host its Frontiers in Brain Health R&D Day on July 21, 2025, featuring expert clinicians discussing the company's CNS pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation. Presentations will include clinical data from Phase 2 and 3 trials of AXS-14, AXS-05, solriamfetol, and AXS-12. The event will be webcast at 11:00 AM Eastern for institutional investors and ...
07-21 11:30
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
<p>Axsome Therapeutics' CEO, Herriot Tabuteau, MD, and the management team will ring the NASDAQ opening bell on July 21, 2025, to celebrate the company's Frontiers in Brain Health R&D Day. This event highlights Axsome's innovative CNS product pipeline and recent U.S. launch of SYMBRAVO®. The ceremony will take place at the Nasdaq MarketSite in New York City, with live coverage starting at 9:20 a.m. ET. Axsome Therapeutics is dedicated to advancin...
07-21 11:00
